Fennec price target lowered to $15 from $22 at Maxim

Maxim analyst Jason McCarthy lowered the firm’s price target on Fennec (FENC) to $15 from $22 but keeps a Buy rating on the shares. Revenue on the pediatric side has been somewhat modest, though with the customer base expanding, Maxim expects this to continue to become more consistent and grow at a modest rate, the analyst tells investors in a research note. The growth focus for Fennec is the AYA – adolescent and young adult – population, the firm added.